Awards & Advancement

EntreMed appoints Ren as interim CEO

Wednesday, April 4, 2012 12:43 PM

EntreMed, a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, has appointed Dr. Ken K. Ren as interim CEO, effective April 2, 2012.

More... »

ACT Oncology names Julia Amo as COO

Wednesday, March 28, 2012 12:02 PM

ACT Oncology, a niche oncology service provider, has appointed Julia Amo, MBA, PMP, as chief operating officer.

More... »

BioHealth names Chappell first entrepreneur-in-residence

Tuesday, March 27, 2012 06:01 AM

BioHealth Innovation (BHI), a new regional private-public partnership, has selected Todd Chappell as the first entrepreneur-in-residence for BHI at the National Institutes of Health (NIH) Office of Technology Transfer (OTT).

More... »

SAFE-BioPharma named Computerworld Laureate

Monday, March 26, 2012 03:49 PM

SAFE-BioPharma, the global digital identity and digital signature standard for the life sciences and healthcare sectors, has been named a 2012 Computerworld Laureate.

More... »

Theorem names Rosenfeld as vice president

Friday, March 23, 2012 03:28 PM

Theorem Clinical Research, a full-service CRO, has appointed Evan Rosenfeld, M.D., J.D., F.C.L.M., as vice president of medical and scientific affairs, medical device and diagnostics.

More... »

Donald P. Rosen named CEO of ACR Image Metrix

Friday, March 23, 2012 03:21 PM

The American College of Radiology (ACR) has named medical imaging contract-research pioneer and distinguished physician, Donald P. Rosen, MD, CEO of ACR Image Metrix, an imaging CRO.

More... »

Genesis Biopharma names Bishop executive chairman

Friday, March 23, 2012 03:12 PM

Genesis Biopharma, a biotechnology company developing targeted cancer immunotherapies, appointed Hans E. Bishop executive chairman of the company's board of directors.

More... »

ImmusanT names Patrick Griffin as chief medical officer, senior VP

Monday, March 19, 2012 12:37 PM

ImmusanT, a privately-held biotech based in Cambridge, Mass., has named Patrick H. Griffin, MD, as chief medical officer and senior vice president of development.

More... »

XTL Biopharma raises capital $3.5 million through institutional investors

Monday, March 19, 2012 11:14 AM

XTL Biopharmaceuticals, based in Herzliya, Israel, has successfully completed a private placement of securities with foreign and Israeli institutional and private investors for a total of $2.4 million, with a 6-month lock-up period.

More... »

NIH awards Avaxia Biologics $1.5 million for bowel disease

Monday, March 19, 2012 10:57 AM

Avaxia Biologics, a privately-held biotech company based in Lexington, Mass., has received a second round of funding from the National Institutes of Health (NIH) to develop orally-active antibody therapeutics for the treatment of inflammatory bowel disease (IBD).

More... »